4.6 Article

Three Months of High-Fructose Feeding Fails to Induce Excessive Weight Gain or Leptin Resistance in Mice

Journal

PLOS ONE
Volume 9, Issue 9, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0107206

Keywords

-

Funding

  1. National Institutes of Health [HL084207, R15AG37959-1]
  2. American Heart Association [14EIA18860041]

Ask authors/readers for more resources

High-fructose diets have been implicated in obesity via impairment of leptin signaling in humans and rodents. We investigated whether fructose-induced leptin resistance in mice could be used to study the metabolic consequences of fructose consumption in humans, particularly in children and adolescents. Male C57Bl/6 mice were weaned to a randomly assigned diet: high fructose, high sucrose, high fat, or control (sugar-free, low-fat). Mice were maintained on their diets for at least 14 weeks. While fructose-fed mice regularly consumed more kcal and expended more energy, there was no difference in body weight compared to control by the end of the study. Additionally, after 14 weeks, both fructose-fed and control mice displayed similar leptin sensitivity. Fructose-feeding also did not change circulating glucose, triglycerides, or free fatty acids. Though fructose has been linked to obesity in several animal models, our data fail to support a role for fructose intake through food lasting 3 months in altering of body weight and leptin signaling in mice. The lack of impact of fructose in the food of growing mice on either body weight or leptin sensitivity over this time frame was surprising, and important information for researchers interested in fructose and body weight regulation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Failure to vasodilate in response to salt loading blunts renal blood flow and causes salt-sensitive hypertension

Jing Wu, Larry N. Agbor, Shi Fang, Masashi Mukohda, Anand R. Nair, Pablo Nakagawa, Avika Sharma, Donald A. Morgan, Justin L. Grobe, Kamal Rahmouni, Robert M. Weiss, James A. McCormick, Curt D. Sigmund

Summary: Our study found that mice expressing a dominant-negative mutation of peroxisome proliferator-activated receptor gamma in vascular smooth muscle developed salt-sensitive hypertension during a high salt diet, with impaired vasodilation in systemic and renal vessels occurring before hypertension onset. The impairment of vasodilation after salt loading led to increased peripheral vascular resistance.

CARDIOVASCULAR RESEARCH (2021)

Article Endocrinology & Metabolism

Hypothalamic MC4R regulates glucose homeostasis through adrenaline-mediated control of glucose reabsorption via renal GLUT2 in mice

Leticia Maria de Souza Cordeiro, Arwa Elsheikh, Nagavardhini Devisetty, Donald A. Morgan, Steven N. Ebert, Kamal Rahmouni, Kavaljit H. Chhabra

Summary: The study found that MC4R-deficient mice, whether obese or weight-matched, exhibited improved glucose tolerance due to increased glucosuria. Selective MC4R deficiency in the paraventricular nucleus of the hypothalamus (PVH) lowered the renal threshold for glucose as measured by a graded [C-13(6)]glucose infusion technique. MC4R deficiency also suppressed renal sympathetic nerve activity and decreased circulating adrenaline and renal GLUT2 levels in mice, contributing to elevated glucosuria.

DIABETOLOGIA (2021)

Review Pharmacology & Pharmacy

Nicotine' actions on energy balance: Friend or foe?

Patricia Seoane-Collazo, Carlos Dieguez, Ruben Nogueiras, Kamal Rahmouni, Jose Manuel Fernandez-Real, Miguel Lopez

Summary: Nicotine exerts significant regulatory effects on energy balance through various pathways, affecting body weight and energy metabolism, and may have potential value as a complementary approach to obesity treatment given the limited efficiency of current therapies.

PHARMACOLOGY & THERAPEUTICS (2021)

Article Peripheral Vascular Disease

mTORC1 (Mechanistic Target of Rapamycin Complex 1) Signaling in Endothelial and Smooth Muscle Cells Is Required for Vascular Function

John J. Reho, Deng-Fu Guo, Donald A. Morgan, Kamal Rahmouni

Summary: mTORC1 functions as a molecular hub and intracellular energy sensor regulating various cellular processes, showing strong implications for cardiovascular function and diseases. Selective disruption of mTORC1 through conditional Raptor gene deletion in endothelial or smooth muscle cells alters vascular function. Endothelial-specific Raptor deletion reduces relaxation responses in the aorta, while smooth muscle cell-specific deletion reduces both endothelial- and smooth muscle-dependent relaxation responses in the aorta, indicating a critical role of mTORC1 signaling in vascular endothelial and smooth muscle function.

HYPERTENSION (2021)

Article Endocrinology & Metabolism

BBSome ablation in SF1 neurons causes obesity without comorbidities

Mohamed Rouabhi, Deng-Fu Guo, Donald A. Morgan, Zhiyong Zhu, Miguel Lopez, Leonid Zingman, Justin L. Grobe, Kamal Rahmouni

Summary: The study revealed that the SF1 neuron BBSome is crucial for regulating energy homeostasis by modulating sympathetic nervous system activity, affecting body weight, fat content, and energy expenditure. Additionally, the SF1 neuron BBSome plays a key role in the development of obesity-related comorbidities.

MOLECULAR METABOLISM (2021)

Article Physiology

Vascular effects of disrupting endothelial mTORC1 signaling in obesity

John J. Reho, Deng-Fu Guo, Andreas M. Beyer, Lauren Wegman-Points, Gary L. Pierce, Kamal Rahmouni

Summary: The study suggests that obesity leads to increased vascular mTORC1 signaling, but this activation does not seem to be necessary for the development of endothelial dysfunction in obesity.

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2021)

Article Biochemistry & Molecular Biology

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Stephen A. Harrison, Peter J. Ruane, Bradley L. Freilich, Guy Neff, Rashmee Patil, Cynthia A. Behling, Chen Hu, Erica Fong, Brittany de Temple, Erik J. Tillman, Timothy P. Rolph, Andrew Cheng, Kitty Yale

Summary: The study demonstrated the efficacy of efruxifermin in treating NASH by significantly reducing HFF levels in patients, with an acceptable safety profile.

NATURE MEDICINE (2021)

Article Pharmacology & Pharmacy

Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats

Erik J. Tillman, William J. Brock, Tim Rolph

Summary: Efruxifermin is an FGF21 analogue that can reduce weight gain and decrease urine volume without increasing sympathetic tone.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Review Peripheral Vascular Disease

BBSome: a New Player in Hypertension and Other Cardiovascular Risks

Yuying Zhao, Kamal Rahmouni

Summary: The BBSome is a protein complex associated with Bardet-Biedl syndrome (BBS) and has been linked to various cardiovascular conditions. It was initially believed to be involved in cilia function, but further studies have shown its role in multiple cellular processes, including receptor localization and gene expression. Animal models have helped uncover the importance of the BBSome in cardiovascular regulation, such as blood pressure control, renal function, vascular reactivity, and cardiac development. The BBSome also plays a critical role in key systems involved in cardiovascular control, including the renin-angiotensin system.

HYPERTENSION (2022)

Article Physiology

T cell-specific deficiency in BBSome component BBS1 interferes with selective immune responses

Madeliene Stump, Deng Fu Guo, Kamal Rahmouni

Summary: Bsardet-Biedl syndrome (BBS) is a genetic condition associated with various clinical features. This study shows that mice lacking the Bbs1 gene in T cells have smaller spleens and impaired skin repair, suggesting an important role of the BBSome in immune function and skin repair.

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2023)

Article Endocrinology & Metabolism

Metabolic consequences of skeletal muscle- and liver-specific BBSome deficiency

Younes Rouabhi, Deng-Fu Guo, Yuying Zhao, Kamal Rahmouni

Summary: The BBSome protein complex plays an important role in metabolic regulation, especially in skeletal muscle and liver. Disruption of the BBSome in skeletal muscle has minimal effects on body weight and glucose handling, but improves insulin sensitivity in female mice. On the other hand, loss of the BBSome in hepatocytes leads to increased body weight, impaired glucose handling, and insulin sensitivity due to attenuated insulin signaling and reduced insulin receptor levels in the plasma membrane caused by mitochondrial dysfunction.

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2023)

Article Endocrinology & Metabolism

Liver-derived FGF21 is essential for full adaptation to ketogenic diet but does not regulate glucose homeostasis

Mikiko Watanabe, Garima Singhal, Ffolliott M. Fisher, Thomas C. Beck, Donald A. Morgan, Fabio Socciarelli, Marie L. Mather, Renata Risi, Jared Bourke, Kamal Rahmouni, Owen P. McGuinness, Jeffrey S. Flier, Eleftheria Maratos-Flier

ENDOCRINE (2020)

No Data Available